Long-term capital, deployed by a highly experienced team, enabling a new generation of companies to grow
/ / /
Gurnet Point Capital is a unique healthcare fund founded by Ernesto Bertarelli and Christopher A. Viehbacher. Together, as both executives and investors, they have many years of expertise in an industry for which they share a passion.
As Managing Partner, Chris has brought together a team of experienced professionals to invest long-term capital and to support entrepreneurs in building a new generation of companies. Based in Cambridge, Massachusetts, and with an office in San Francisco, Gurnet Point Capital has an initial capital allocation of $2 billion. Its remit in healthcare is global, encompassing life sciences and medical technologies.
In Ernesto Bertarelli and Waypoint Capital, Gurnet Point has a partner that is similarly committed on a long-term bigger picture. This allows it to forge synergies across its portfolio of investments, which means that it can draw upon considerable know-how in clinical trial design and execution, value-driven drug development, regulatory affairs, toxicology and other areas related to bringing early-stage medicines and devices to patients.
The fund invests across all stages of product development through to commercialisation and does so with an approach that is a hybrid of venture and private equity investing strategies. It is governed by a guiding tenet that even the earliest of technologies must present a clear commercial case, benefiting both patients and the healthcare system as a whole.
Consistent with the amount of capital, time and energy that it dedicates, Gurnet Point Capital will generally seek to be, over time, the majority – or at least principal - investor in each of its companies.